N@N

Oxygen Biotherapeutics Inc (NASDAQ:OXBT), Down By 5.17% ($0.03) From $0.580 After BUYINS.NET Report Predicted Weakness After Ea

^{Published on 2012-12-17 07:41:53 - WOPRAI}
 

December 17, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, December 13th 2012 stating that Oxygen Biotherapeutics Inc (NASDAQ:OXBT) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=oxbt&id=334723

At the time this story was written, Oxygen Biotherapeutics Inc (NASDAQ:OXBT) is Down By 5.17% ($0.03) From $0.580 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Oxygen Biotherapeutics Inc (NASDAQ:OXBT) - Oxygen Biotherapeutics, Inc. develops medical and cosmetic products that deliver oxygen to tissues in the body. It develops a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery for conditions, including but not limited to traumatic brain injury, decompression sickness, cosmetics, and topical wounds. The companys under development product include Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions. In addition, it out-licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. Further, Oxygen Biotherapeutics offers Dermacyte line of oxygen-rich skin care products that promote the appearance of skin health and other desirable cosmetic benefits; and Wundecyte, a wound-healing gel. The company markets and sells Dermacyte line of products through www.buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales and exclusive distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics was founded in 1967 and is based in Durham, North Carolina..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Oxygen Biotherapeutics Inc (NASDAQ:OXBT) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net